102 related articles for article (PubMed ID: 37327187)
1. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P; Robert ME; Zhang X
Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM; Marin JJG; Lamarca A; Rodrigues PM; Khan SA; Roberts LR; Cardinale V; Carpino G; Andersen JB; Braconi C; Calvisi DF; Perugorria MJ; Fabris L; Boulter L; Macias RIR; Gaudio E; Alvaro D; Gradilone SA; Strazzabosco M; Marzioni M; Coulouarn C; Fouassier L; Raggi C; Invernizzi P; Mertens JC; Moncsek A; Rizvi S; Heimbach J; Koerkamp BG; Bruix J; Forner A; Bridgewater J; Valle JW; Gores GJ
Nat Rev Gastroenterol Hepatol; 2020 Sep; 17(9):557-588. PubMed ID: 32606456
[TBL] [Abstract][Full Text] [Related]
4. Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices.
Evans M; Kendall T
Expert Rev Mol Diagn; 2024 May; 24(5):393-408. PubMed ID: 38752560
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
Zhang C; You X; Zhang Q; Wang D
Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
[TBL] [Abstract][Full Text] [Related]
6. How Molecular Discoveries Have Changed Liver Tumor Pathology: A Brief Review.
Taheri N; Graham RP
Arch Pathol Lab Med; 2024 May; 148(5):e96-e102. PubMed ID: 37639429
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S
Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing.
Stenzinger A; Vogel A; Lehmann U; Lamarca A; Hofman P; Terracciano L; Normanno N
Cancer Treat Rev; 2024 Jan; 122():102649. PubMed ID: 37984132
[TBL] [Abstract][Full Text] [Related]
9. Cancer review: Cholangiocarcinoma.
Ghouri YA; Mian I; Blechacz B
J Carcinog; 2015; 14():1. PubMed ID: 25788866
[TBL] [Abstract][Full Text] [Related]
10. Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications.
Lee SH; Song SY
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730713
[TBL] [Abstract][Full Text] [Related]
11. Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.
Yáñez-Bartolomé M; Serra-Camprubí Q; Arenas EJ; Escorihuela M; Castet F; Fabregat-Franco C; Querol J; Arribas J; Peiró S; Macarulla T; Tian TV
Methods Mol Biol; 2024; 2806():139-151. PubMed ID: 38676801
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.
Li C; Bie L; Chen M; Ying J
Explor Target Antitumor Ther; 2023; 4(6):1310-1327. PubMed ID: 38213535
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma.
Yang JD; Ghoz H; Aboelsoud MM; Taylor WR; Yab TC; Berger CK; Cao X; Foote PH; Giama NH; Barr Fritcher EG; Mahoney DW; Moser CD; Smyrk TC; Kipp BR; Gores GJ; Roberts LR; Kisiel JB
Hepatol Commun; 2021 Aug; 5(8):1448-1459. PubMed ID: 34430788
[TBL] [Abstract][Full Text] [Related]
14. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Sarantis P; Tzanetatou ED; Ioakeimidou E; Vallilas C; Androutsakos T; Damaskos C; Garmpis N; Garmpi A; Papavassiliou AG; Karamouzis MV
Am J Transl Res; 2021; 13(12):13246-13260. PubMed ID: 35035673
[TBL] [Abstract][Full Text] [Related]
15. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.
Cardinale V; Carpino G; Reid L; Gaudio E; Alvaro D
World J Gastrointest Oncol; 2012 May; 4(5):94-102. PubMed ID: 22645632
[TBL] [Abstract][Full Text] [Related]
16. Case report: Robust response to sintilimab in advanced distal cholangiocarcinoma with PD-L1 expression and DNA damage repair.
He W; Song C; Ren J; Ji X; Wang X; Liu L
Front Pharmacol; 2024; 15():1336699. PubMed ID: 38659574
[TBL] [Abstract][Full Text] [Related]
17. Options in Targeted Therapy for Advanced Cholangiocarcinoma: A 2024 Update.
Oprescu Macovei AM; Venter DP; Makkai GG; Valcea S; Venter MD; Tulin A; Stefan M; Constantin O
Cureus; 2024 May; 16(5):e59793. PubMed ID: 38846220
[TBL] [Abstract][Full Text] [Related]
18. Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.
Zhang Z; Zhang W
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):772-775. PubMed ID: 37886181
[No Abstract] [Full Text] [Related]
19. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment.
Czekay RP; Higgins CE; Aydin HB; Samarakoon R; Subasi NB; Higgins SP; Lee H; Higgins PJ
Cells; 2024 May; 13(10):. PubMed ID: 38786020
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
Choi JH; Thung SN
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
